Focus on Front Line and establish an urgent need to treat patients as early as possible to delay recurrence.
Key Selling Message
Front-line Avastin significantly delays recurrence in patients with Stage IIIb–IV ovarian cancer
- Convince clinicians that treating in FL as early as possible maximises PFI with 20% more patients progression free 6 months after completion of chemotherapy.
- Continue to establish PFS benefit in FL patients when Avastin is continued beyond chemotherapy OS data in high risk Stage IV patients.